

Blepharospasm

[View the current Blepharospasm InDepth page on BioPortfolio.com](#) ([PDF](#))

(<http://www.bioportfolio.com/indepth/Blepharospasm.html>) - Regularly Updated.

A blepharospasm is any abnormal tic or twitch of the eyelid . However, it is normally distinguished from less serious disorders and refers to Benign Essential Blepharospasm, a focal dystonia of the muscles around the eyes. The cause is often undetermined, but fatigue or an irritant are possible contributing factors. Symptoms usually last for a few days then disappear without treatment, but in some cases the twitching is chronic and persistent. Occasionally, the symptoms are severe enough to result in effective blindness. ([From the Wikipedia article Blepharospasm](#).)

Recent Publications on Blepharospasm:



- [A family with a hereditary form of torsion dystonia from Northern Sweden treated with bilateral pallidal deep brain stimulation.](#)
*To evaluate pallidal DBS in a non-DYT1 form of hereditary dystonia. We...*6th November, 2009
Department of Neurosurgery, University Hospital of Northern Sweden, Umea,- *Mov Disord.* 2009 Nov 4. ([DOI Direct Link](#))
- [Use of Botulinum A Toxin \(BOTOX\) in Different Types of Facial Dystonia.](#)
*This study was carried out in the Eye Departments of Combined Military...*6th November, 2009
Department of Ophthalmology, Combined Military Hospital, Kharian Cantt.- *J Coll Physicians Surg Pak.* 2009 Nov;19(11):742-3. ([DOI Direct Link](#))
- [\[5/6 Care and treatment of the aged\]](#)
*Botulism is a severe neuromuscular disease caused by toxins produced by...*5th November, 2009
- *Soins Gerontol.* 2009 Sep-Oct;(79):45-6.
- [Feline entropion: a case series of 50 affected animals \(2003-2008\).](#)
*AIM: To evaluate the signalment, clinical signs, and etiopathogenesis of...*29th October, 2009
Department of Veterinary Medicine, University of Cambridge, Cambridge CB3- *Vet Ophthalmol.* 2009 Jul-Aug;12(4):221-6. ([DOI Direct Link](#))
- [Botulinum toxin in facial rejuvenation: an update.](#)
*Since its initial approval by the US Food and Drug Administration (FDA) 20...*24th October, 2009
Department of Ophthalmology and Visual Sciences, University of British- *Dermatol Clin.* 2009 Oct;27(4):417-25, v. ([DOI Direct Link](#))
- [Abnormalities induced in reciprocal inhibition between orbicularis oculi and levator palpebrae following peripheral facial palsy.](#)
*Peripheral Facial palsy (PFP) is generally considered a benign condition...*23rd October, 2009
Electromyography Unit, Department of Clinical Neurophysiology, University- *Electromyogr Clin Neurophysiol.* 2009 Sep-Oct;49(6-7):299-304.
- [Botulism and vaccines for its prevention.](#)
*Botulism is a severe neuromuscular disease caused by toxins produced by...*20th October, 2009

- Medical Countermeasures Technology, U.S. Army Medical Research and- Vaccine. 2009 Nov 5;27 Suppl 4:D33-9. ([DOI Direct Link](#))
- [Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?](#)
*OBJECTIVES: As the indications and duration of treatment of botulinum...*9th October, 2009
 Institute for Pharmacology and Toxicology, Hannover Medical University,- Clin Neuropharmacol. 2009 Jul-Aug;32(4):213-8. ([DOI Direct Link](#))
 - [Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.](#)
*PURPOSE: To compare the efficacies and safeties of Meditoxin (Medy-Tox,...*2nd October, 2009
 Department of Ophthalmology, Institute of Vision Research, University of- Korean J Ophthalmol. 2009 Sep;23(3):137-41. Epub 2009 Sep 8. ([DOI Direct Link](#))
 - [\[18q syndrome associated with blepharospasm\]](#)
*AIM: To evaluate the signalment, clinical signs, and etiopathogenesis of...*1st October, 2009
 - Rev Neurol. 2009 Jul 16-31;49(2):112.
 - [Speech-induced blepharospasm.](#)
*Primary blepharospasm is an adult-onset dystonia typically present at rest...*26th September, 2009
 Department of Neurological and Psychiatric Sciences, University of Bari,- Neurol Sci. 2009 Sep 25. ([DOI Direct Link](#))
 - [Lower limb involvement in adult-onset primary dystonia: frequency and clinical features.](#)
*Background and purpose: Despite the growing number of reports describing...*22nd September, 2009
 Department of Neurological and Psychiatric Sciences, University of Bari,- Eur J Neurol. 2009 Sep 17. ([DOI Direct Link](#))
 - [\[Hemifacial spasm\]](#)
*Hemifacial spasm is one of the two most common craniofacial movement...*5th September, 2009
 Service de neurologie, CNRS UMR 8160, CHU d'Amiens, 80054 Amiens cedex.- Ann Dermatol Venereol. 2009 May;136 Suppl 4:S142-5. ([DOI Direct Link](#))
 - [Cognitive disturbances in primary blepharospasm.](#)
*The common belief that primary dystonia is a purely motor disorder with no...*26th August, 2009
 Parkinson's Disease and Movement Disorders Program, Hospital de Clinicas- Mov Disord. 2009 Oct 30;24(14):2112-20. ([DOI Direct Link](#))
 - [Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.](#)
*PurposeTo investigate the long-term effectiveness and safety of botulinum...*4th August, 2009
 Dipartimento Universitario di Neuroscienze Cliniche, Sezione di- Eye. 2009 Jul 24. ([DOI Direct Link](#))

BioNews Results for Blepharospasm

- [Research points to expanding role of botulinum toxin in several urologic procedures](#)
Urology Times: Nov 4 2009 4:06AM Matching: blepharospasm
- [No difference in pain between 30-, 32-gauge needles for periocular botulinum toxin type A injections](#)
OSN Super Site: Oct 15 2009 5:06PM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data For NT 201 In Post-stroke Upper Limb Spasticity](#)
Medical News Today: Oct 7 2009 10:38AM Matching: blepharospasm
- [Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone](#)
News-Medical.Net: Oct 7 2009 5:41AM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
Pharma Live: Oct 7 2009 3:22AM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
PR Newswire: Oct 6 2009 9:53PM Matching: blepharospasm

- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
PR Newswire: Oct 6 2009 9:53PM Matching: blepharospasm
- [Merz Pharmaceuticals, LLC Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
BioSpace: Oct 6 2009 6:15PM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
Interest!ALERT: Oct 6 2009 5:21PM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
Street Insider: Oct 6 2009 4:31PM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
SmartBrief: Oct 6 2009 4:24PM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
Portland Business Journal: Oct 6 2009 4:22PM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
Baltimore Business Journal: Oct 6 2009 4:15PM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
PR Newswire via Yahoo!: Oct 6 2009 4:07PM Matching: blepharospasm
- [Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity](#)
Yahoo! Canada: Oct 6 2009 4:04PM Matching: blepharospasm

Blepharospasm Clinical Trials:



- [A Study of Acetyl Hexapeptide-8 \(AH8\) in Treatment of Blepharospasm](#)

Blepharospasm Patents:



- 7399607- [Fluorescence polarization assays for determining clostridial toxin activity](#)
- 7459164- [Composition for therapeutic and cosmetic botulinum toxin](#)
- 7462699- [BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy](#)
- 7465458- [Methods for treating eye disorders](#)
- 7468188- [Multi-step therapy for injured muscles](#)
- 7468189- [Neuropathic pain treatment method](#)
- 7473679- [Treatments employing neuronal exocytosis-inhibiting peptides](#)
- 7479281- [Botulinum toxin for treating postherpetic neuralgia](#)
- 7479481- [Treatment of ocular diseases and disorders using lantibiotic compositions](#)
- 7485624- [Method for treating cardiac muscle disorders](#)
- 7488294- [Biosensors, communicators, and controllers monitoring eye movement and methods for using](#)

[them](#)

- [7455845- Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure](#)
- [7452697- Chromatographic method and system for purifying a botulinum toxin](#)
- [7449192- Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction](#)
- [7404969- Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules](#)
- [7410995- N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders](#)
- [7413742- Clostridial toxin derivatives and methods for treating pain](#)
- [7419675- Method for treating peritoneal adhesions](#)
- [7422753- Methods for treating trichotillomania](#)
- [7425338- Clostridial toxin derivatives and methods for treating pain](#)
- [7429386- Stretch mark treatment](#)
- [7431935- Proteins within the type E botulinum neurotoxin complex](#)
- [7438921- Buttock deformity treatment](#)
- [7445914- Animal product free media and processes for obtaining a botulinum toxin](#)
- [7491403- Pharmaceutical botulinum toxin compositions](#)
- [7491799- Modified botulinum neurotoxins](#)
- [7537773- Chemodenervating pharmaceutical as anti-inflammatory agent](#)
- [7538114- Glycine transporter-1 inhibitors](#)
- [7556817- Clostridial toxin activatable Clostridial toxins](#)
- [7560251- Media for Clostridium bacterium](#)
- [7572792- Azetidine glycine transporter inhibitors](#)
- [7576083- Morpholinyl piperidine glycine transporter inhibitors](#)
- [7579010- Botulinum toxin pharmaceutical compositions with a recombinant human serum albumin](#)
- [7585996- Acyloxyalkyl carbamate prodrugs, methods of synthesis and use](#)
- [7589057- Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems](#)
- [7592350- Polycyclic compounds as potent alpha2-adrenoceptor antagonists](#)
- [7534863- Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins](#)
- [7531572- Acyloxyalkyl carbamate prodrugs of .alpha.-amino acids, methods of synthesis and use](#)
- [7531183- Biologically active hemagglutinin from type A Clostridium botulinum and methods of use](#)
- [7494654- Compositions and methods for treating cardiovascular conditions with botulinum toxin](#)
- [7494661- Methods for using tetanus toxin for beneficial purposes in animals \(mammals\)](#)
- [7495069- FRET protease assays for botulinum serotype A/E toxins](#)
- [7498361- Methods of treating tardive dyskinesia and other movement disorders](#)
- [7501130- Methods for treating myofascial pain](#)
- [7514088- Multivalent Clostridial toxin derivatives and methods of their use](#)
- [7514099- Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules](#)
- [7515054- Biosensors, communicators, and controllers monitoring eye movement and methods for using them](#)
- [7517864- RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid \(siNA\)](#)
- [7531179- BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy](#)
- [7608275- Systems and methods for delivery of a therapeutic agent](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

